Results 181 to 190 of about 92,949 (326)

Perspectives for Advancing Biotechnological Succinic Acid Production

open access: yesMicrobial Biotechnology, Volume 19, Issue 5, May 2026.
Succinic acid is an important molecule for sustainable chemical manufacturing, but its industrial production faces high costs and sustainability challenges, which are linked to feedstocks and excessive acid/base consumption. This opinion explores production routes based on next‐generation feedstocks and low‐pH fermentations to inspire novel cost ...
Christoph Gunkel, Bastian Blombach
wiley   +1 more source

The Mitochondrial NAD Transporter SLC25A51 in Adipocytes Regulates Adipose Tissue Mitochondrial Function and Systemic Metabolism During Aging

open access: yesAging Cell, Volume 25, Issue 5, May 2026.
We revealed the pathophysiological significance and therapeutic potential of adipocyte mitochondrial NAD transporter, namely solute carrier family 25 member 51 (SLC25A51), in age‐associated metabolic diseases, particularly adipose tissue mitochondrial function, obesity, and insulin resistance, by analyzing adipocyte‐specific Slc25a51 knockout (ASKO ...
Daiki Kojima   +19 more
wiley   +1 more source

Citrate‐Dependent Activation of Acetyl CoA Carboxylase Promotes Renal Lipid Accumulation in a Rat Model of Chronic Kidney Disease

open access: yesActa Physiologica, Volume 242, Issue 5, May 2026.
ABSTRACT Background Abnormal accumulation of lipids within the kidney contributes to the progression of chronic kidney disease, but the underlying metabolic mechanisms remain unclear. Citrate is a central metabolite in cellular energy regulation and is frequently elevated in advanced kidney disease, yet its impact on renal lipid metabolism has not been
Marta Sanz‐Gómez   +8 more
wiley   +1 more source

Review Article: Targeting Peroxisome Proliferator‐Activated Receptors in Primary Biliary Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, Volume 63, Issue 9, Page 1215-1235, May 2026.
Peroxisome proliferator‐activated receptor (PPAR) agonists have emerged as important second‐line treatments in primary biliary cholangitis, with profiles influenced by different selectivity for α‐, δ‐ and γ‐isoforms. PPAR‐α and PPAR‐δ agonism improve cholestasis, with inflammation reduced via all isoforms. PPAR‐δ agonism also reduces pruritus.
Jörn M. Schattenberg   +8 more
wiley   +1 more source

Is AMP‐activated protein kinase activation a central mechanism of cardio‐metabolic outcomes after metabolic and bariatric surgery?

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 3480-3490, May 2026.
Abstract Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity. It usually results in spectacular weight loss, associated with improvements of obesity‐associated comorbidities. The mechanisms underlying these benefits are not fully understood but could involve a postoperative activation of the enzyme 5′ AMP‐activated ...
Adrien Delcour, Nathalie Niederhoffer
wiley   +1 more source

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug‐Target Mendelian Randomization Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4091-4099, May 2026.
ABSTRACT Aims Observational studies show metformin use associated with lower cancer risk, although experimental evidence is inconsistent. To provide genetic validation for repositioning of metformin in cancer prevention, we assessed genetically proxied effects of putative metformin targets on cancer outcomes using a drug‐target Mendelian randomization (
Xingyu Shen   +7 more
wiley   +1 more source

Human Acetyl-CoA Carboxylase 2 [PDF]

open access: yesJournal of Biological Chemistry, 1997
Lutfi Abu-Elheiga   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy